chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Anticoagulant therapy, Brain death, Cerebral haemorrhage, Cerebral mass effect, Death
Clinical narrative: CVST; This spontaneous report was received from a consumer (the patient's brother-in-law) and concerned a 37 year-old female patient. The patient's weight and height were not reported, nor was her medical history, mother of 2 year-old child and a 5 year-old child. The patient received COVID-19 vaccine Ad26.COV2.S (suspension for injection, intramuscular, batch number not reported), dose, vaccination date and anatomical site of administration not reported, for prophylactic vaccination. The batch number was not reported and will be requested. No concomitant medications were reported. On 06-SEP-2021, approximately 1 week post-vaccination, the reporter contacted the company to report that the patient had experienced cerebral venous sinus thrombosis (CVST), was fighting for her life 'confirmed that night, a direct reaction to your vaccine', and that the patient's prognosis was dire. The patient had been hospitalized on an unspecified date. On 15:52 hours on 07-SEP-2021, the reporter contacted the company again to report that life support for the patient was to be discontinued in 38 minutes. It was not reported if life support was subsequently withdrawn and if the patient had died. The action taken with COVID-19 vaccine Ad26.COV2.S was not applicable. The outcomes of CVST was not reported. This report was serious (life-threatening, caused/prolonged hospitalization).; Sender's Comments: V0: This spontaneous report received from a consumer (the patient's brother-in-law) concerned a 37-year-old female patient who experienced CVST approximately 1 week after vaccine. Medical history and concomitant medications were not reported. Approximately 1 week after vaccine, the reporter contacted the company to report that the patient had experienced cerebral venous sinus thrombosis (CVST), was fighting for her life 'confirmed that night, a direct reaction to your vaccine', and that the patient's prospects were dire. The patient had been hospitalized on an unspecified date. Laboratory values, including platelet count, d dimer and anti-PF4 antibodies were not provided. The following day, the reporter contacted the company again to report that life support for the patient was to be discontinued in 38 minutes. It was not reported if life support was subsequently withdrawn or if the patient had died. Information is limited in this case, and the occurrence of CVST could represent background incidence of such events in the general population. It was not reported whether there was thrombocytopenia or other risk factors. However, a relationship with Janssen Covid-19 vaccine cannot be ruled out and thus the relationship is considered indeterminate. Additional information has been requested.
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Decompressive craniectomy, Immunoglobulin therapy, Loss of consciousness, Thrombosis with thrombocytopenia syndrome, Unresponsive to stimuli
Clinical narrative: CVST; This spontaneous report was received from a consumer (the patient's brother-in-law) and concerned a 37 year-old female patient. The patient's weight and height were not reported, nor was her medical history, mother of 2 year-old child and a 5 year-old child. The patient received COVID-19 vaccine Ad26.COV2.S (suspension for injection, intramuscular, batch number not reported), dose, vaccination date and anatomical site of administration not reported, for prophylactic vaccination. The batch number was not reported and will be requested. No concomitant medications were reported. On 06-SEP-2021, approximately 1 week post-vaccination, the reporter contacted the company to report that the patient had experienced cerebral venous sinus thrombosis (CVST), was fighting for her life 'confirmed that night, a direct reaction to your vaccine', and that the patient's prognosis was dire. The patient had been hospitalized on an unspecified date. On 15:52 hours on 07-SEP-2021, the reporter contacted the company again to report that life support for the patient was to be discontinued in 38 minutes. It was not reported if life support was subsequently withdrawn and if the patient had died. The action taken with COVID-19 vaccine Ad26.COV2.S was not applicable. The outcomes of CVST was not reported. This report was serious (life-threatening, caused/prolonged hospitalization).; Sender's Comments: V0: This spontaneous report received from a consumer (the patient's brother-in-law) concerned a 37-year-old female patient who experienced CVST approximately 1 week after vaccine. Medical history and concomitant medications were not reported. Approximately 1 week after vaccine, the reporter contacted the company to report that the patient had experienced cerebral venous sinus thrombosis (CVST), was fighting for her life 'confirmed that night, a direct reaction to your vaccine', and that the patient's prospects were dire. The patient had been hospitalized on an unspecified date. Laboratory values, including platelet count, d dimer and anti-PF4 antibodies were not provided. The following day, the reporter contacted the company again to report that life support for the patient was to be discontinued in 38 minutes. It was not reported if life support was subsequently withdrawn or if the patient had died. Information is limited in this case, and the occurrence of CVST could represent background incidence of such events in the general population. It was not reported whether there was thrombocytopenia or other risk factors. However, a relationship with Janssen Covid-19 vaccine cannot be ruled out and thus the relationship is considered indeterminate. Additional information has been requested.
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Ventricular drainage
Clinical narrative: CVST; This spontaneous report was received from a consumer (the patient's brother-in-law) and concerned a 37 year-old female patient. The patient's weight and height were not reported, nor was her medical history, mother of 2 year-old child and a 5 year-old child. The patient received COVID-19 vaccine Ad26.COV2.S (suspension for injection, intramuscular, batch number not reported), dose, vaccination date and anatomical site of administration not reported, for prophylactic vaccination. The batch number was not reported and will be requested. No concomitant medications were reported. On 06-SEP-2021, approximately 1 week post-vaccination, the reporter contacted the company to report that the patient had experienced cerebral venous sinus thrombosis (CVST), was fighting for her life 'confirmed that night, a direct reaction to your vaccine', and that the patient's prognosis was dire. The patient had been hospitalized on an unspecified date. On 15:52 hours on 07-SEP-2021, the reporter contacted the company again to report that life support for the patient was to be discontinued in 38 minutes. It was not reported if life support was subsequently withdrawn and if the patient had died. The action taken with COVID-19 vaccine Ad26.COV2.S was not applicable. The outcomes of CVST was not reported. This report was serious (life-threatening, caused/prolonged hospitalization).; Sender's Comments: V0: This spontaneous report received from a consumer (the patient's brother-in-law) concerned a 37-year-old female patient who experienced CVST approximately 1 week after vaccine. Medical history and concomitant medications were not reported. Approximately 1 week after vaccine, the reporter contacted the company to report that the patient had experienced cerebral venous sinus thrombosis (CVST), was fighting for her life 'confirmed that night, a direct reaction to your vaccine', and that the patient's prospects were dire. The patient had been hospitalized on an unspecified date. Laboratory values, including platelet count, d dimer and anti-PF4 antibodies were not provided. The following day, the reporter contacted the company again to report that life support for the patient was to be discontinued in 38 minutes. It was not reported if life support was subsequently withdrawn or if the patient had died. Information is limited in this case, and the occurrence of CVST could represent background incidence of such events in the general population. It was not reported whether there was thrombocytopenia or other risk factors. However, a relationship with Janssen Covid-19 vaccine cannot be ruled out and thus the relationship is considered indeterminate. Additional information has been requested.
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Death
Clinical narrative: CVST; This spontaneous report was received from a consumer (the patient's brother-in-law) and concerned a 37 year-old female patient. The patient's weight and height were not reported, nor was her medical history, mother of 2 year-old child and a 5 year-old child. The patient received COVID-19 vaccine Ad26.COV2.S (suspension for injection, intramuscular, batch number not reported), dose, vaccination date and anatomical site of administration not reported, for prophylactic vaccination. The batch number was not reported and will be requested. No concomitant medications were reported. On 06-SEP-2021, approximately 1 week post-vaccination, the reporter contacted the company to report that the patient had experienced cerebral venous sinus thrombosis (CVST), was fighting for her life 'confirmed that night, a direct reaction to your vaccine', and that the patient's prognosis was dire. The patient had been hospitalized on an unspecified date. On 15:52 hours on 07-SEP-2021, the reporter contacted the company again to report that life support for the patient was to be discontinued in 38 minutes. It was not reported if life support was subsequently withdrawn and if the patient had died. The action taken with COVID-19 vaccine Ad26.COV2.S was not applicable. The outcomes of CVST was not reported. This report was serious (life-threatening, caused/prolonged hospitalization).; Sender's Comments: V0: This spontaneous report received from a consumer (the patient's brother-in-law) concerned a 37-year-old female patient who experienced CVST approximately 1 week after vaccine. Medical history and concomitant medications were not reported. Approximately 1 week after vaccine, the reporter contacted the company to report that the patient had experienced cerebral venous sinus thrombosis (CVST), was fighting for her life 'confirmed that night, a direct reaction to your vaccine', and that the patient's prospects were dire. The patient had been hospitalized on an unspecified date. Laboratory values, including platelet count, d dimer and anti-PF4 antibodies were not provided. The following day, the reporter contacted the company again to report that life support for the patient was to be discontinued in 38 minutes. It was not reported if life support was subsequently withdrawn or if the patient had died. Information is limited in this case, and the occurrence of CVST could represent background incidence of such events in the general population. It was not reported whether there was thrombocytopenia or other risk factors. However, a relationship with Janssen Covid-19 vaccine cannot be ruled out and thus the relationship is considered indeterminate. Additional information has been requested.
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Haemorrhage intracranial, Imaging procedure, Infarction, Laboratory test, Platelet count decreased
Clinical narrative: CVST; This spontaneous report was received from a consumer (the patient's brother-in-law) and concerned a 37 year-old female patient. The patient's weight and height were not reported, nor was her medical history, mother of 2 year-old child and a 5 year-old child. The patient received COVID-19 vaccine Ad26.COV2.S (suspension for injection, intramuscular, batch number not reported), dose, vaccination date and anatomical site of administration not reported, for prophylactic vaccination. The batch number was not reported and will be requested. No concomitant medications were reported. On 06-SEP-2021, approximately 1 week post-vaccination, the reporter contacted the company to report that the patient had experienced cerebral venous sinus thrombosis (CVST), was fighting for her life 'confirmed that night, a direct reaction to your vaccine', and that the patient's prognosis was dire. The patient had been hospitalized on an unspecified date. On 15:52 hours on 07-SEP-2021, the reporter contacted the company again to report that life support for the patient was to be discontinued in 38 minutes. It was not reported if life support was subsequently withdrawn and if the patient had died. The action taken with COVID-19 vaccine Ad26.COV2.S was not applicable. The outcomes of CVST was not reported. This report was serious (life-threatening, caused/prolonged hospitalization).; Sender's Comments: V0: This spontaneous report received from a consumer (the patient's brother-in-law) concerned a 37-year-old female patient who experienced CVST approximately 1 week after vaccine. Medical history and concomitant medications were not reported. Approximately 1 week after vaccine, the reporter contacted the company to report that the patient had experienced cerebral venous sinus thrombosis (CVST), was fighting for her life 'confirmed that night, a direct reaction to your vaccine', and that the patient's prospects were dire. The patient had been hospitalized on an unspecified date. Laboratory values, including platelet count, d dimer and anti-PF4 antibodies were not provided. The following day, the reporter contacted the company again to report that life support for the patient was to be discontinued in 38 minutes. It was not reported if life support was subsequently withdrawn or if the patient had died. Information is limited in this case, and the occurrence of CVST could represent background incidence of such events in the general population. It was not reported whether there was thrombocytopenia or other risk factors. However, a relationship with Janssen Covid-19 vaccine cannot be ruled out and thus the relationship is considered indeterminate. Additional information has been requested.
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Thrombosis, Thrombosis with thrombocytopenia syndrome
Clinical narrative: CVST; This spontaneous report was received from a consumer (the patient's brother-in-law) and concerned a 37 year-old female patient. The patient's weight and height were not reported, nor was her medical history, mother of 2 year-old child and a 5 year-old child. The patient received COVID-19 vaccine Ad26.COV2.S (suspension for injection, intramuscular, batch number not reported), dose, vaccination date and anatomical site of administration not reported, for prophylactic vaccination. The batch number was not reported and will be requested. No concomitant medications were reported. On 06-SEP-2021, approximately 1 week post-vaccination, the reporter contacted the company to report that the patient had experienced cerebral venous sinus thrombosis (CVST), was fighting for her life 'confirmed that night, a direct reaction to your vaccine', and that the patient's prognosis was dire. The patient had been hospitalized on an unspecified date. On 15:52 hours on 07-SEP-2021, the reporter contacted the company again to report that life support for the patient was to be discontinued in 38 minutes. It was not reported if life support was subsequently withdrawn and if the patient had died. The action taken with COVID-19 vaccine Ad26.COV2.S was not applicable. The outcomes of CVST was not reported. This report was serious (life-threatening, caused/prolonged hospitalization).; Sender's Comments: V0: This spontaneous report received from a consumer (the patient's brother-in-law) concerned a 37-year-old female patient who experienced CVST approximately 1 week after vaccine. Medical history and concomitant medications were not reported. Approximately 1 week after vaccine, the reporter contacted the company to report that the patient had experienced cerebral venous sinus thrombosis (CVST), was fighting for her life 'confirmed that night, a direct reaction to your vaccine', and that the patient's prospects were dire. The patient had been hospitalized on an unspecified date. Laboratory values, including platelet count, d dimer and anti-PF4 antibodies were not provided. The following day, the reporter contacted the company again to report that life support for the patient was to be discontinued in 38 minutes. It was not reported if life support was subsequently withdrawn or if the patient had died. Information is limited in this case, and the occurrence of CVST could represent background incidence of such events in the general population. It was not reported whether there was thrombocytopenia or other risk factors. However, a relationship with Janssen Covid-19 vaccine cannot be ruled out and thus the relationship is considered indeterminate. Additional information has been requested.
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Cerebral venous sinus thrombosis
Clinical narrative: CVST; This spontaneous report was received from a consumer (the patient's brother-in-law) and concerned a 37 year-old female patient. The patient's weight and height were not reported, nor was her medical history, mother of 2 year-old child and a 5 year-old child. The patient received COVID-19 vaccine Ad26.COV2.S (suspension for injection, intramuscular, batch number not reported), dose, vaccination date and anatomical site of administration not reported, for prophylactic vaccination. The batch number was not reported and will be requested. No concomitant medications were reported. On 06-SEP-2021, approximately 1 week post-vaccination, the reporter contacted the company to report that the patient had experienced cerebral venous sinus thrombosis (CVST), was fighting for her life 'confirmed that night, a direct reaction to your vaccine', and that the patient's prognosis was dire. The patient had been hospitalized on an unspecified date. On 15:52 hours on 07-SEP-2021, the reporter contacted the company again to report that life support for the patient was to be discontinued in 38 minutes. It was not reported if life support was subsequently withdrawn and if the patient had died. The action taken with COVID-19 vaccine Ad26.COV2.S was not applicable. The outcomes of CVST was not reported. This report was serious (life-threatening, caused/prolonged hospitalization).; Sender's Comments: V0: This spontaneous report received from a consumer (the patient's brother-in-law) concerned a 37-year-old female patient who experienced CVST approximately 1 week after vaccine. Medical history and concomitant medications were not reported. Approximately 1 week after vaccine, the reporter contacted the company to report that the patient had experienced cerebral venous sinus thrombosis (CVST), was fighting for her life 'confirmed that night, a direct reaction to your vaccine', and that the patient's prospects were dire. The patient had been hospitalized on an unspecified date. Laboratory values, including platelet count, d dimer and anti-PF4 antibodies were not provided. The following day, the reporter contacted the company again to report that life support for the patient was to be discontinued in 38 minutes. It was not reported if life support was subsequently withdrawn or if the patient had died. Information is limited in this case, and the occurrence of CVST could represent background incidence of such events in the general population. It was not reported whether there was thrombocytopenia or other risk factors. However, a relationship with Janssen Covid-19 vaccine cannot be ruled out and thus the relationship is considered indeterminate. Additional information has been requested.
Age: 60.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Headache, Myalgia, Pyrexia, Rash
Clinical narrative: rash that started on lower legs initially and eventually had head to toe rash/hives that lasted for a week. aches, headache, chills, and a fever that lasted several days. Highest temp 100.9.
Age: 60.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Chills, Headache, Pain, Pyrexia, Rash
Clinical narrative: rash that started on lower legs initially and eventually had head to toe rash/hives that lasted for a week. aches, headache, chills, and a fever that lasted several days. Highest temp 100.9.
Age: 60.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Urticaria
Clinical narrative: rash that started on lower legs initially and eventually had head to toe rash/hives that lasted for a week. aches, headache, chills, and a fever that lasted several days. Highest temp 100.9.
Age: 50.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Seizure
Clinical narrative: Had a seizure; high fever; headache; This is a spontaneous report from a contactable consumer (patient). A 50-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number: 30145BA), via an unspecified route of administration in the left arm on 18Sep2021 at 10:15 (at the age of 50-year-old), dose 1, single for COVID-19 immunisation. The patient had no medical history. The patent's concomitant medications included trazodone; vitamin D nos; vitamin B complex. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19, did not receive other vaccines four weeks prior. The patient was not pregnant at the time of vaccination. On 19Sep2021 at 03:30, the patient had a seizure and followed by headache and high fever. No treatment was received for the events. The patient had not been tested for COVID-19 since vaccination. The outcome of the evens was recovered.  Information on the lot/batch number has been requested.
Age: 50.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Headache, Pyrexia, Seizure
Clinical narrative: Had a seizure; high fever; headache; This is a spontaneous report from a contactable consumer (patient). A 50-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number: 30145BA), via an unspecified route of administration in the left arm on 18Sep2021 at 10:15 (at the age of 50-year-old), dose 1, single for COVID-19 immunisation. The patient had no medical history. The patent's concomitant medications included trazodone; vitamin D nos; vitamin B complex. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19, did not receive other vaccines four weeks prior. The patient was not pregnant at the time of vaccination. On 19Sep2021 at 03:30, the patient had a seizure and followed by headache and high fever. No treatment was received for the events. The patient had not been tested for COVID-19 since vaccination. The outcome of the evens was recovered.  Information on the lot/batch number has been requested.
Age: 57.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: White blood cell count normal
Clinical narrative: felt as though he was having a heart attack and went to the emergency room; just ate dinner and felt like his heart was vibrating; checked his blood pressure in left arm with home monitor and it was 151 or something; keep having the problems and weird chest pain for a couple of hours; did have a couple of episodes of weird heart beating, they called ventricular ectopic beats and supraventricular ectopic beats; chest tightness; shortness of breath; did have a couple of episodes of weird heart beating, they called ventricular ectopic beats and supraventricular ectopic beats; did have a couple of episodes of weird heart beating, they called ventricular ectopic beats and supraventricular ectopic beats; This is a spontaneous report from a contactable consumer report for self. This 57-year-old male patient received second dose of bnt162b2 (BNT162B2), via an unspecified route of administration, administered in left arm on 01Jun2021 (Batch/Lot Number: EW0185) (vaccinated at the 57-year-old) as dose 2, single for covid-19 immunisation. None medical history. Patient was pretty active and works out 3-4 times a week and eats healthy. There were no concomitant medications. Patient received first dose on 11May2021 with Lot number: EW0185. Patient stated he felt as though he was having a heart attack and went to the emergency room on 11Aug2021. He received the first Covid vaccine on 11May2021 and the second one on 01Jun2021. He stayed at the hospital and was admitted and released the next afternoon and discharged. Clinical course was: He had keep having the problems and weird chest pain for a couple of hours. Had just ate dinner and felt like his heart was vibrating and that was why he went to the hospital. Has a home blood pressure monitor and he checked his blood pressure in left arm and it was 151 and he had not worked out or anything only walked from the living area to the dining room and that was the extent of that and so he knew something was going on. The cardiologist at the hospital stated something was going on but they did not know what. He had to wear a heart monitor for 2 weeks and mostly everything was good, but he did have a couple of episodes of weird heart beating, they called ventricular ectopic beats and supraventricular ectopic beats. States all has improved, but he has the occasional chest pain, chest tightness, and shortness of breath. The symptoms all seem to be declining, but he still gets it every now and then. No one in his family has ever had any heart issues or adverse events from vaccines and that's going back 3 generations to his great-grandparents. They did a Cat scan and everything appeared normal during the scan, Troponin T test and the highest was at 52 and then hours later is was 42. Had a chest X-ray and that seemed good, the Cat scan showed no issues contributing. With the heart thing was told that they cannot exclude premature ventricular complexes. The outcome of heart attack, heart was vibrating, blood pressure increased was recovering, Chest pain, chest tightness, was not recovered, other events outcome was unknown.
Age: 66.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Abdominal discomfort, Anxiety, Arthralgia, Atrial fibrillation, Blood test
Clinical narrative: thyroiditis/ acute inflammation; AFIB; Platelet count high; Alpha 1 and Alpha 2 Globulin High; Alpha 1 and Alpha 2 Globulin High; Sciatica; Hip pain after severe; neuropathy like symptoms with both leg involvement; lung nodules; Prostatitis; short of breath; chest pains; Lung infection and inflammation/ feels this is infectious/inflammatory process; Lung infection and inflammation/ feels this is infectious/inflammatory process; Lung infection and inflammation/ feels this is infectious/inflammatory process; This is a spontaneous report from a contactable consumer (patient). A 66-year-old male patient received BNT162B2, via an unspecified route of administration on 25Mar2021 15:00 (Batch/Lot Number: ER8727) at the age of 66 years old as dose 2, single for COVID-19 immunisation. Medical history included chronic obstructive pulmonary disease (COPD) and enlarged prostate; on 17Feb2021, acute pancreatitis, meningomyelocele (MMC) hospitalization followed by Dr; lung infection and inflammation, has had numerous scans for several years to keep watch on these "nodules" which come and go. No known allergies. Concomitant medication(s) included fluticasone furoate, umeclidinium bromide, vilanterol trifenatate (TRELEGY ELLIPTA) taken for an unspecified indication, start and stop date were not reported. The patient previously received first dose of BNT162B2 (Batch/Lot Number: EN6198) on 04Mar2021 14:00. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. On 26Mar2021 (day after), the patient experienced short of breath and chest pains. Within 3 days increased shortness of breath. On 10Aug2021, difficulty urinating - prostatitis. Improved. BACTRIM twice daily X 6 weeks. On 11Aug2021, consult with Dr for lung nodules. Lung infection and inflammation Has had numerous scans for several years to keep watch on these nodules which come and go. He feels this is infectious/inflammatory process (in 2021). Started on Amoxicillin 500 mg-potassium clavulanate 125 mg tablet Twice daily X 10 days. On 19Aug2021, sciatica/neuropathy like symptoms with both leg involvement, hip pain after severe. On 31Aug2021, bloodwork done for autoimmune disorders (unknown results). Gabapentin now BID. Platelet count high. Alpha 1 and Alpha 2 Globulin High. On 01Sep2021, atrial fibrillation (AFIB). On 16Sep2021 thyroiditis, bloodwork showing acute inflammation. Events resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Treatment was received for events including antibiotic, prednisone, many testing and physical. No hospitalization prolonged. The outcome of the events was recovering. The case was not assessed as not serious by the reporter.  Follow-up attempts are completed. No further information is expected.
Age: 66.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Blood thyroid stimulating hormone, Chest pain, Computerised tomogram, Death of relative, Dizziness
Clinical narrative: thyroiditis/ acute inflammation; AFIB; Platelet count high; Alpha 1 and Alpha 2 Globulin High; Alpha 1 and Alpha 2 Globulin High; Sciatica; Hip pain after severe; neuropathy like symptoms with both leg involvement; lung nodules; Prostatitis; short of breath; chest pains; Lung infection and inflammation/ feels this is infectious/inflammatory process; Lung infection and inflammation/ feels this is infectious/inflammatory process; Lung infection and inflammation/ feels this is infectious/inflammatory process; This is a spontaneous report from a contactable consumer (patient). A 66-year-old male patient received BNT162B2, via an unspecified route of administration on 25Mar2021 15:00 (Batch/Lot Number: ER8727) at the age of 66 years old as dose 2, single for COVID-19 immunisation. Medical history included chronic obstructive pulmonary disease (COPD) and enlarged prostate; on 17Feb2021, acute pancreatitis, meningomyelocele (MMC) hospitalization followed by Dr; lung infection and inflammation, has had numerous scans for several years to keep watch on these "nodules" which come and go. No known allergies. Concomitant medication(s) included fluticasone furoate, umeclidinium bromide, vilanterol trifenatate (TRELEGY ELLIPTA) taken for an unspecified indication, start and stop date were not reported. The patient previously received first dose of BNT162B2 (Batch/Lot Number: EN6198) on 04Mar2021 14:00. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. On 26Mar2021 (day after), the patient experienced short of breath and chest pains. Within 3 days increased shortness of breath. On 10Aug2021, difficulty urinating - prostatitis. Improved. BACTRIM twice daily X 6 weeks. On 11Aug2021, consult with Dr for lung nodules. Lung infection and inflammation Has had numerous scans for several years to keep watch on these nodules which come and go. He feels this is infectious/inflammatory process (in 2021). Started on Amoxicillin 500 mg-potassium clavulanate 125 mg tablet Twice daily X 10 days. On 19Aug2021, sciatica/neuropathy like symptoms with both leg involvement, hip pain after severe. On 31Aug2021, bloodwork done for autoimmune disorders (unknown results). Gabapentin now BID. Platelet count high. Alpha 1 and Alpha 2 Globulin High. On 01Sep2021, atrial fibrillation (AFIB). On 16Sep2021 thyroiditis, bloodwork showing acute inflammation. Events resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Treatment was received for events including antibiotic, prednisone, many testing and physical. No hospitalization prolonged. The outcome of the events was recovering. The case was not assessed as not serious by the reporter.  Follow-up attempts are completed. No further information is expected.
Age: 66.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Dysphagia, Dyspnoea, Dysuria, Fall, Heart rate increased
Clinical narrative: thyroiditis/ acute inflammation; AFIB; Platelet count high; Alpha 1 and Alpha 2 Globulin High; Alpha 1 and Alpha 2 Globulin High; Sciatica; Hip pain after severe; neuropathy like symptoms with both leg involvement; lung nodules; Prostatitis; short of breath; chest pains; Lung infection and inflammation/ feels this is infectious/inflammatory process; Lung infection and inflammation/ feels this is infectious/inflammatory process; Lung infection and inflammation/ feels this is infectious/inflammatory process; This is a spontaneous report from a contactable consumer (patient). A 66-year-old male patient received BNT162B2, via an unspecified route of administration on 25Mar2021 15:00 (Batch/Lot Number: ER8727) at the age of 66 years old as dose 2, single for COVID-19 immunisation. Medical history included chronic obstructive pulmonary disease (COPD) and enlarged prostate; on 17Feb2021, acute pancreatitis, meningomyelocele (MMC) hospitalization followed by Dr; lung infection and inflammation, has had numerous scans for several years to keep watch on these "nodules" which come and go. No known allergies. Concomitant medication(s) included fluticasone furoate, umeclidinium bromide, vilanterol trifenatate (TRELEGY ELLIPTA) taken for an unspecified indication, start and stop date were not reported. The patient previously received first dose of BNT162B2 (Batch/Lot Number: EN6198) on 04Mar2021 14:00. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. On 26Mar2021 (day after), the patient experienced short of breath and chest pains. Within 3 days increased shortness of breath. On 10Aug2021, difficulty urinating - prostatitis. Improved. BACTRIM twice daily X 6 weeks. On 11Aug2021, consult with Dr for lung nodules. Lung infection and inflammation Has had numerous scans for several years to keep watch on these nodules which come and go. He feels this is infectious/inflammatory process (in 2021). Started on Amoxicillin 500 mg-potassium clavulanate 125 mg tablet Twice daily X 10 days. On 19Aug2021, sciatica/neuropathy like symptoms with both leg involvement, hip pain after severe. On 31Aug2021, bloodwork done for autoimmune disorders (unknown results). Gabapentin now BID. Platelet count high. Alpha 1 and Alpha 2 Globulin High. On 01Sep2021, atrial fibrillation (AFIB). On 16Sep2021 thyroiditis, bloodwork showing acute inflammation. Events resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Treatment was received for events including antibiotic, prednisone, many testing and physical. No hospitalization prolonged. The outcome of the events was recovering. The case was not assessed as not serious by the reporter.  Follow-up attempts are completed. No further information is expected.
Age: 66.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Hyperthyroidism, Insomnia, Magnetic resonance imaging pancreas, Nausea, Neuropathy peripheral
Clinical narrative: thyroiditis/ acute inflammation; AFIB; Platelet count high; Alpha 1 and Alpha 2 Globulin High; Alpha 1 and Alpha 2 Globulin High; Sciatica; Hip pain after severe; neuropathy like symptoms with both leg involvement; lung nodules; Prostatitis; short of breath; chest pains; Lung infection and inflammation/ feels this is infectious/inflammatory process; Lung infection and inflammation/ feels this is infectious/inflammatory process; Lung infection and inflammation/ feels this is infectious/inflammatory process; This is a spontaneous report from a contactable consumer (patient). A 66-year-old male patient received BNT162B2, via an unspecified route of administration on 25Mar2021 15:00 (Batch/Lot Number: ER8727) at the age of 66 years old as dose 2, single for COVID-19 immunisation. Medical history included chronic obstructive pulmonary disease (COPD) and enlarged prostate; on 17Feb2021, acute pancreatitis, meningomyelocele (MMC) hospitalization followed by Dr; lung infection and inflammation, has had numerous scans for several years to keep watch on these "nodules" which come and go. No known allergies. Concomitant medication(s) included fluticasone furoate, umeclidinium bromide, vilanterol trifenatate (TRELEGY ELLIPTA) taken for an unspecified indication, start and stop date were not reported. The patient previously received first dose of BNT162B2 (Batch/Lot Number: EN6198) on 04Mar2021 14:00. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. On 26Mar2021 (day after), the patient experienced short of breath and chest pains. Within 3 days increased shortness of breath. On 10Aug2021, difficulty urinating - prostatitis. Improved. BACTRIM twice daily X 6 weeks. On 11Aug2021, consult with Dr for lung nodules. Lung infection and inflammation Has had numerous scans for several years to keep watch on these nodules which come and go. He feels this is infectious/inflammatory process (in 2021). Started on Amoxicillin 500 mg-potassium clavulanate 125 mg tablet Twice daily X 10 days. On 19Aug2021, sciatica/neuropathy like symptoms with both leg involvement, hip pain after severe. On 31Aug2021, bloodwork done for autoimmune disorders (unknown results). Gabapentin now BID. Platelet count high. Alpha 1 and Alpha 2 Globulin High. On 01Sep2021, atrial fibrillation (AFIB). On 16Sep2021 thyroiditis, bloodwork showing acute inflammation. Events resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Treatment was received for events including antibiotic, prednisone, many testing and physical. No hospitalization prolonged. The outcome of the events was recovering. The case was not assessed as not serious by the reporter.  Follow-up attempts are completed. No further information is expected.
Age: 66.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Pain in extremity, Pancreatitis acute, Paraesthesia, Platelet count increased, Positron emission tomogram
Clinical narrative: thyroiditis/ acute inflammation; AFIB; Platelet count high; Alpha 1 and Alpha 2 Globulin High; Alpha 1 and Alpha 2 Globulin High; Sciatica; Hip pain after severe; neuropathy like symptoms with both leg involvement; lung nodules; Prostatitis; short of breath; chest pains; Lung infection and inflammation/ feels this is infectious/inflammatory process; Lung infection and inflammation/ feels this is infectious/inflammatory process; Lung infection and inflammation/ feels this is infectious/inflammatory process; This is a spontaneous report from a contactable consumer (patient). A 66-year-old male patient received BNT162B2, via an unspecified route of administration on 25Mar2021 15:00 (Batch/Lot Number: ER8727) at the age of 66 years old as dose 2, single for COVID-19 immunisation. Medical history included chronic obstructive pulmonary disease (COPD) and enlarged prostate; on 17Feb2021, acute pancreatitis, meningomyelocele (MMC) hospitalization followed by Dr; lung infection and inflammation, has had numerous scans for several years to keep watch on these "nodules" which come and go. No known allergies. Concomitant medication(s) included fluticasone furoate, umeclidinium bromide, vilanterol trifenatate (TRELEGY ELLIPTA) taken for an unspecified indication, start and stop date were not reported. The patient previously received first dose of BNT162B2 (Batch/Lot Number: EN6198) on 04Mar2021 14:00. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. On 26Mar2021 (day after), the patient experienced short of breath and chest pains. Within 3 days increased shortness of breath. On 10Aug2021, difficulty urinating - prostatitis. Improved. BACTRIM twice daily X 6 weeks. On 11Aug2021, consult with Dr for lung nodules. Lung infection and inflammation Has had numerous scans for several years to keep watch on these nodules which come and go. He feels this is infectious/inflammatory process (in 2021). Started on Amoxicillin 500 mg-potassium clavulanate 125 mg tablet Twice daily X 10 days. On 19Aug2021, sciatica/neuropathy like symptoms with both leg involvement, hip pain after severe. On 31Aug2021, bloodwork done for autoimmune disorders (unknown results). Gabapentin now BID. Platelet count high. Alpha 1 and Alpha 2 Globulin High. On 01Sep2021, atrial fibrillation (AFIB). On 16Sep2021 thyroiditis, bloodwork showing acute inflammation. Events resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Treatment was received for events including antibiotic, prednisone, many testing and physical. No hospitalization prolonged. The outcome of the events was recovering. The case was not assessed as not serious by the reporter.  Follow-up attempts are completed. No further information is expected.
Age: 66.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Productive cough, Prostatitis, Pulmonary mass, Sciatica, Thyroiditis
Clinical narrative: thyroiditis/ acute inflammation; AFIB; Platelet count high; Alpha 1 and Alpha 2 Globulin High; Alpha 1 and Alpha 2 Globulin High; Sciatica; Hip pain after severe; neuropathy like symptoms with both leg involvement; lung nodules; Prostatitis; short of breath; chest pains; Lung infection and inflammation/ feels this is infectious/inflammatory process; Lung infection and inflammation/ feels this is infectious/inflammatory process; Lung infection and inflammation/ feels this is infectious/inflammatory process; This is a spontaneous report from a contactable consumer (patient). A 66-year-old male patient received BNT162B2, via an unspecified route of administration on 25Mar2021 15:00 (Batch/Lot Number: ER8727) at the age of 66 years old as dose 2, single for COVID-19 immunisation. Medical history included chronic obstructive pulmonary disease (COPD) and enlarged prostate; on 17Feb2021, acute pancreatitis, meningomyelocele (MMC) hospitalization followed by Dr; lung infection and inflammation, has had numerous scans for several years to keep watch on these "nodules" which come and go. No known allergies. Concomitant medication(s) included fluticasone furoate, umeclidinium bromide, vilanterol trifenatate (TRELEGY ELLIPTA) taken for an unspecified indication, start and stop date were not reported. The patient previously received first dose of BNT162B2 (Batch/Lot Number: EN6198) on 04Mar2021 14:00. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. On 26Mar2021 (day after), the patient experienced short of breath and chest pains. Within 3 days increased shortness of breath. On 10Aug2021, difficulty urinating - prostatitis. Improved. BACTRIM twice daily X 6 weeks. On 11Aug2021, consult with Dr for lung nodules. Lung infection and inflammation Has had numerous scans for several years to keep watch on these nodules which come and go. He feels this is infectious/inflammatory process (in 2021). Started on Amoxicillin 500 mg-potassium clavulanate 125 mg tablet Twice daily X 10 days. On 19Aug2021, sciatica/neuropathy like symptoms with both leg involvement, hip pain after severe. On 31Aug2021, bloodwork done for autoimmune disorders (unknown results). Gabapentin now BID. Platelet count high. Alpha 1 and Alpha 2 Globulin High. On 01Sep2021, atrial fibrillation (AFIB). On 16Sep2021 thyroiditis, bloodwork showing acute inflammation. Events resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Treatment was received for events including antibiotic, prednisone, many testing and physical. No hospitalization prolonged. The outcome of the events was recovering. The case was not assessed as not serious by the reporter.  Follow-up attempts are completed. No further information is expected.
Age: 66.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Tremor, Weight decreased
Clinical narrative: thyroiditis/ acute inflammation; AFIB; Platelet count high; Alpha 1 and Alpha 2 Globulin High; Alpha 1 and Alpha 2 Globulin High; Sciatica; Hip pain after severe; neuropathy like symptoms with both leg involvement; lung nodules; Prostatitis; short of breath; chest pains; Lung infection and inflammation/ feels this is infectious/inflammatory process; Lung infection and inflammation/ feels this is infectious/inflammatory process; Lung infection and inflammation/ feels this is infectious/inflammatory process; This is a spontaneous report from a contactable consumer (patient). A 66-year-old male patient received BNT162B2, via an unspecified route of administration on 25Mar2021 15:00 (Batch/Lot Number: ER8727) at the age of 66 years old as dose 2, single for COVID-19 immunisation. Medical history included chronic obstructive pulmonary disease (COPD) and enlarged prostate; on 17Feb2021, acute pancreatitis, meningomyelocele (MMC) hospitalization followed by Dr; lung infection and inflammation, has had numerous scans for several years to keep watch on these "nodules" which come and go. No known allergies. Concomitant medication(s) included fluticasone furoate, umeclidinium bromide, vilanterol trifenatate (TRELEGY ELLIPTA) taken for an unspecified indication, start and stop date were not reported. The patient previously received first dose of BNT162B2 (Batch/Lot Number: EN6198) on 04Mar2021 14:00. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. On 26Mar2021 (day after), the patient experienced short of breath and chest pains. Within 3 days increased shortness of breath. On 10Aug2021, difficulty urinating - prostatitis. Improved. BACTRIM twice daily X 6 weeks. On 11Aug2021, consult with Dr for lung nodules. Lung infection and inflammation Has had numerous scans for several years to keep watch on these nodules which come and go. He feels this is infectious/inflammatory process (in 2021). Started on Amoxicillin 500 mg-potassium clavulanate 125 mg tablet Twice daily X 10 days. On 19Aug2021, sciatica/neuropathy like symptoms with both leg involvement, hip pain after severe. On 31Aug2021, bloodwork done for autoimmune disorders (unknown results). Gabapentin now BID. Platelet count high. Alpha 1 and Alpha 2 Globulin High. On 01Sep2021, atrial fibrillation (AFIB). On 16Sep2021 thyroiditis, bloodwork showing acute inflammation. Events resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Treatment was received for events including antibiotic, prednisone, many testing and physical. No hospitalization prolonged. The outcome of the events was recovering. The case was not assessed as not serious by the reporter.  Follow-up attempts are completed. No further information is expected.